12:00 AM
 | 
Jun 22, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bromfenac: Phase II data

In a Phase II trial in 38 patients, a low-dose formulation of Xibrom twice daily for 42 days met the primary endpoint of significantly improving the objective sign of conjunctival staining from baseline as measured by the...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >